89bio to Participate in Upcoming Investor Conferences
<!-- Name:DistributionId Value:8829624 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:True -->
<!-- Name:IcbCode Value:4573 -->…
Browsing Tag
89bio
89bio Announces Publication of Results of Phase 1b/2a Study of Pegozafermin for the Treatment of…
– Data from cohorts 1-6 in the proof-of-concept study showed pegozafermin was generally well tolerated and had beneficial therapeutic effect in reducing liver fat and improving markers of liver injury, fibrosis and lipids – – …
89bio Reports Positive Topline Results from an Expansion Cohort of the Phase 1b/2a Trial of…
63% of patients achieved 2-point or greater improvement in NAS without worsening of fibrosis; clinically meaningful improvements on registration enabling endpoints of NASH resolution (32%) and fibrosis improvement (26%)Robust changes on…
89bio Presents New Data from Phase 1b/2a NASH Study Showing BIO89-100 Reduces Spleen Volume
New sub-analysis presented at The Liver Meeting® 2021 shows treatment with BIO89-100 reduced spleen volume by an average of 11.8% in NASH patients Oral presentation was highlighted by the AASLD Scientific Program Committee as a key…
89bio to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
SAN FRANCISCO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and…